OCPD
MCID: OBS003
MIFTS: 46

Obsessive-Compulsive Personality Disorder (OCPD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Personality Disorder

MalaCards integrated aliases for Obsessive-Compulsive Personality Disorder:

Name: Obsessive-Compulsive Personality Disorder 12 74 15
Obsessive-Compulsive Personality 54 71
Anankastic Personality Disorder 12 32
Compulsive Personality Disorder 43 71
Obsessional Personality Disorder 71
Ocpd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10932
ICD9CM 34 301.4
MeSH 43 D003193
NCIt 49 C92638
SNOMED-CT 67 112091009
ICD10 32 F60.5
UMLS 71 C0009595 C1704373 C3714689

Summaries for Obsessive-Compulsive Personality Disorder

Disease Ontology : 12 A personality disorder that is characterized by a pervasive pattern of preoccupation with orderliness, perfectionism, and mental and interpersonal control at the expense of flexibility, openness, and efficiency.

MalaCards based summary : Obsessive-Compulsive Personality Disorder, also known as obsessive-compulsive personality, is related to avoidant personality disorder and personality disorder. An important gene associated with Obsessive-Compulsive Personality Disorder is DRD3 (Dopamine Receptor D3), and among its related pathways/superpathways are Bacterial invasion of epithelial cells and Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and digestive/alimentary

Wikipedia : 74 Obsessive-compulsive personality disorder (OCPD) is a personality disorder characterized by excessive... more...

Related Diseases for Obsessive-Compulsive Personality Disorder

Diseases related to Obsessive-Compulsive Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.2 WASF2 WASF1 SLC6A4 PIR CLPS
2 personality disorder 30.9 SLC6A4 HTR2A DRD3 COMT
3 histrionic personality disorder 30.5 WASF2 WASF1 PIR
4 separation anxiety disorder 30.4 WASF2 WASF1 SLC6A4
5 borderline personality disorder 30.1 SLC6A4 HTR2A COMT
6 hypochondriasis 30.0 SLITRK1 SLC6A4 PIR HTR2A
7 obsessive-compulsive disorder 30.0 SLITRK1 SLC6A4 HTR2A DRD3 COMT
8 anxiety 29.9 SLC6A4 HTR2A DRD3 COMT
9 anorexia nervosa 29.9 SLC6A4 HTR2A COMT
10 neurotic disorder 29.9 SLC6A4 HTR2A
11 panic disorder 29.8 SLC6A4 HTR2A DRD3 COMT
12 major depressive disorder 29.8 SLC6A4 HTR2A DRD3 COMT
13 schizotypal personality disorder 29.6 WASF2 WASF1 PIR COMT CLPS
14 eating disorder 29.6 SLC6A4 SHC4 HTR2A DRD3 COMT
15 generalized anxiety disorder 29.5 SLC6A4 HTR2A COMT
16 bulimia nervosa 29.5 SLC6A4 HTR2A COMT
17 social phobia 29.5 WASF2 WASF1 SLC6A4 COMT
18 mental depression 29.3 WASF2 WASF1 SLC6A4 HTR2A DRD3 COMT
19 mood disorder 29.3 SLC6A4 HTR2A DRD3 COMT
20 intermittent explosive disorder 29.2 SLITRK1 SLC6A4 HTR2A COMT
21 alcohol dependence 29.1 SLC6A4 HTR2A DRD3 COMT
22 tic disorder 28.9 SLITRK1 SLC6A4 HTR2A DRD3 COMT
23 gilles de la tourette syndrome 28.9 SLITRK1 SLC6A4 HTR2A DRD3 COMT
24 disease of mental health 28.7 WASF2 WASF1 SLC6A4 HTR2A DRD3 COMT
25 severe combined immunodeficiency 10.6
26 depression 10.6
27 supranuclear palsy, progressive, 1 10.4
28 barbiturate abuse 10.3 WASF2 WASF1
29 attention deficit-hyperactivity disorder 10.3
30 chronic tic disorder 10.3 SLITRK1 DRD3
31 pyromania 10.3 WASF1 SLITRK1
32 paranoid personality disorder 10.2 WASF2 WASF1 PIR
33 asperger syndrome 10.2
34 ehlers-danlos syndrome, hypermobility type 10.1
35 multiple system atrophy 1 10.1
36 autism 10.1
37 autism spectrum disorder 10.1
38 paraphilia disorder 10.1
39 ehlers-danlos syndrome 10.1
40 hypermobility syndrome 10.1
41 temporal lobe epilepsy 10.1
42 essential tremor 10.1
43 hypermobile ehlers-danlos syndrome 10.1
44 periodontal ehlers-danlos syndrome 10.1
45 tremor 10.1
46 spinocerebellar ataxia, autosomal recessive 3 10.1 WASF2 WASF1
47 delusional disorder 10.1 HTR2A DRD3
48 kleptomania 10.1 SLITRK1 SLC6A4 DRD3
49 alcoholic psychosis 10.1 SLC6A4 HTR2A
50 somatization disorder 10.1 SLC6A4 HTR2A

Comorbidity relations with Obsessive-Compulsive Personality Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Personality Disorder:



Diseases related to Obsessive-Compulsive Personality Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Personality Disorder

MGI Mouse Phenotypes related to Obsessive-Compulsive Personality Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 CLPS COMT DRD3 HTR2A JMJD6 NAPB
2 digestive/alimentary MP:0005381 9.5 CLPS DRD3 HTR2A JMJD6 SLC6A4 WASF1
3 nervous system MP:0003631 9.28 CLPS COMT DRD3 JMJD6 NAPB SLC6A4

Drugs & Therapeutics for Obsessive-Compulsive Personality Disorder

Drugs for Obsessive-Compulsive Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
10
Haloperidol Approved Phase 4 52-86-8 3559
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Ondansetron Approved Phase 4 99614-02-5 4595
13
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
14
Cycloserine Approved Phase 4 68-41-7 401 6234
15
Citalopram Approved Phase 4 59729-33-8 2771
16
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
19
Sertraline Approved Phase 4 79617-96-2 68617
20
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
21
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
22 Quetiapine Fumarate Phase 4 111974-72-2
23 Antidepressive Agents, Tricyclic Phase 4
24 Dopamine Agents Phase 4
25 Dopamine Antagonists Phase 4
26 Hormones Phase 4
27 calcium channel blockers Phase 4
28 Central Nervous System Stimulants Phase 4
29 Hypoglycemic Agents Phase 4
30 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
31 Duloxetine Hydrochloride Phase 4
32 Haloperidol decanoate Phase 4
33 Antipsychotic Agents Phase 4
34 Gastrointestinal Agents Phase 4
35 Antiemetics Phase 4
36 Dermatologic Agents Phase 4
37 Serotonin Receptor Agonists Phase 4
38 Acidophilus Phase 4
39 Sulfalene Phase 4
40 Bifidobacterium Phase 4
41 Anti-Bacterial Agents Phase 4
42 Anti-Infective Agents Phase 4
43 Antitubercular Agents Phase 4
44 Antibiotics, Antitubercular Phase 4
45 Antimetabolites Phase 4
46 Analgesics Phase 4
47 Calcium, Dietary Phase 4
48 Antiparkinson Agents Phase 4
49 Analgesics, Non-Narcotic Phase 4
50 Antirheumatic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 378)
# Name Status NCT ID Phase Drugs
1 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
2 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
3 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
4 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
5 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
6 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
7 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
8 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
9 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
10 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
11 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
12 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
13 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
14 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
15 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
16 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
17 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Completed NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
18 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
19 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
20 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
21 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
22 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
23 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
24 Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD Recruiting NCT03993535 Phase 4 selective serotonin reuptake inhibitor
25 A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder Recruiting NCT02334644 Phase 4
26 Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. Active, not recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
27 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
28 Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder Active, not recruiting NCT00640133 Phase 4
29 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Not yet recruiting NCT04015596 Phase 4 Naproxen Sodium
30 The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms Not yet recruiting NCT04336228 Phase 4 Escitalopram;Placebo oral tablet
31 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
32 SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
33 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
34 A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
35 Pharmacogenetics in Primary Care Psychotropics Unknown status NCT03232502 Phase 3
36 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study Unknown status NCT02590445 Phase 2, Phase 3
37 Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder Unknown status NCT02375152 Phase 2, Phase 3
38 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
39 Family Based Treatment of Early Childhood OCD Completed NCT00055068 Phase 3
40 A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy Completed NCT00182000 Phase 3 seromycin
41 Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder. Completed NCT01807403 Phase 3
42 A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
43 Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study Completed NCT00000389 Phase 3 Fluvoxamine
44 A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects Completed NCT02229903 Phase 3
45 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
46 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
47 Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial Completed NCT00674219 Phase 3 Memantine
48 Family Based Treatment for Early Childhood OCD Completed NCT00533806 Phase 3
49 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Completed NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
50 Behavior Therapy for Childhood OCD Completed NCT00000386 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Personality Disorder

Cochrane evidence based reviews: compulsive personality disorder

Genetic Tests for Obsessive-Compulsive Personality Disorder

Anatomical Context for Obsessive-Compulsive Personality Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Personality Disorder:

40
Brain, Testes, Cortex, Subthalamic Nucleus, Skin, Caudate Nucleus, Thalamus

Publications for Obsessive-Compulsive Personality Disorder

Articles related to Obsessive-Compulsive Personality Disorder:

(show top 50) (show all 440)
# Title Authors PMID Year
1
Intolerance of uncertainty and obsessive-compulsive personality disorder. 61
32068417 2020
2
Is problematic exercise really problematic? A dimensional approach. 61
30915933 2020
3
Altered spontaneous brain activity in obsessive-compulsive personality disorder. 61
31707312 2020
4
Comparing the interpersonal profiles of obsessive-compulsive personality disorder and avoidant personality disorder: Are there homogeneous profiles or interpersonal subtypes? 61
31944791 2020
5
Work Addiction, Obsessive-Compulsive Personality Disorder, Burn-Out, and Global Burden of Disease: Implications from the ICD-11. 61
31968540 2020
6
Misophonia: Phenomenology, comorbidity and demographics in a large sample. 61
32294104 2020
7
Radically Open Dialectical Behavior Therapy: Social Signaling, Transdiagnostic Utility and Current Evidence. 61
32021506 2020
8
Homicidal Ideation and Forensic Psychopathology: Evidence From the 2016 Nationwide Emergency Department Sample (NEDS). 61
31404481 2020
9
Personality disorders characterized by anxiety predict Alzheimer's disease in women: A case-control studies. 61
31833453 2019
10
Pineal gland volumes are changed in patients with obsessive-compulsive personality disorder. 61
31455564 2019
11
Obsessive-compulsive personality disorder features and response to behavioral therapy for insomnia among patients with hypnotic-dependent insomnia. 61
29869891 2019
12
Problematic use of the Internet is a unidimensional quasi-trait with impulsive and compulsive subtypes. 61
31703666 2019
13
Overlap of obsessive-compulsive personality disorder and autism spectrum disorder traits among OCD outpatients: an exploratory study. 61
31375037 2019
14
Obsessive compulsive personality traits: Understanding the chain of pathogenesis from health to disease. 61
31202047 2019
15
Obsessive-compulsive personality disorder symptoms as a risk factor for postpartum depressive symptoms. 61
30171361 2019
16
Editorial: Hoarding and Obsessive-Compulsive Disorder. 61
31108161 2019
17
Volumetric MRI study of orbito-frontal cortex and thalamus in obsessive-compulsive personality disorder. 61
30962057 2019
18
An epidemiological survey of psychiatric disorders in Iran: Kermanshah. 61
31096141 2019
19
Hippocampus and amygdalar volumes in patients with obsessive-compulsive personality disorder. 61
30962058 2019
20
Psychopathological and psychiatric evaluation of patients affected by lipodystrophy. 61
31144218 2019
21
A Psychometric Examination of the Pathological Obsessive Compulsive Personality Scale (POPS): Initial Study in an Undergraduate Sample. 61
29494778 2019
22
Crossed obsessive-compulsive personality disorder and impaired theory of mind in temporal lobe epilepsy. 61
30554354 2019
23
Association between cognitive impairments and obsessive-compulsive spectrum presentations following traumatic brain injury. 61
28043199 2019
24
The concurrent validity of a Web-based self-report assessment for personality disorders. 61
30592174 2019
25
Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder. 61
30353921 2019
26
[Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity]. 61
29490380 2019
27
The role of personality disorders in obsessive-compulsive disorder. 61
30745684 2019
28
Obsessive-Compulsive Personality Symptoms Predict Poorer Response to Gamma Ventral Capsulotomy for Intractable OCD. 61
31998155 2019
29
Psychological impact of fibromyalgia: current perspectives. 61
30858740 2019
30
Personality disorder traits in young adults with subclinical obsessive-compulsive symptoms: Not just traits related to obsessive- compulsive personality. 61
31380698 2019
31
Obsessive, compulsive, and conscientious? The relationship between OCPD and personality traits. 61
29272027 2018
32
Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis. 61
30261937 2018
33
Problematic overstudying: Studyholism or study addiction? 61
30541335 2018
34
The relationship between obsessive compulsive personality and obsessive compulsive disorder treatment outcomes: Predictive utility and clinically significant change - CORRIGENDUM. 61
29615137 2018
35
[The psychiatric comorbidity of anorexia nervosa: A comparative study in a population of French and Greek anorexic patients]. 61
29102367 2018
36
Recovery and Nonrecovery After Psychotherapy With Transference Interpretation: Two Case Studies. 61
30049221 2018
37
Psychic euosmia and obsessive compulsive personality disorder. 61
30254981 2018
38
Examining the DSM-5 alternative model of personality disorders operationalization of obsessive-compulsive personality disorder in a mental health sample. 61
29927297 2018
39
Gambling disorder and obsessive-compulsive personality disorder: A frequent but understudied comorbidity. 61
29936850 2018
40
ICD-11 and DSM-5 personality trait domains capture categorical personality disorders: Finding a common ground. 61
28835108 2018
41
Psychiatric (Axis I) and personality (Axis II) disorders and subjective psychiatric symptoms in chronic tinnitus. 61
29188734 2018
42
Psychological Factors Including Demographic Features, Mental Illnesses, and Personality Disorders as Predictors in Internet Addiction Disorder. 61
29997655 2018
43
Anxiety, Mood, and Personality Disorders in Patients with Benign Paroxysmal Positional Vertigo. 61
30042641 2018
44
Associations Between Personality Disorder Characteristics, Psychological Symptoms, and Sexual Functioning in Young Women. 61
29276043 2018
45
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. 61
29067550 2018
46
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. 61
29024130 2018
47
Development and Examination of the Five-Factor Obsessive-Compulsive Inventory-Short Form. 61
27095820 2018
48
Substance-use disorders, personality traits, and sex differences in institutionalized adolescents. 61
30067395 2018
49
Suicidality in People With Obsessive-Compulsive Symptoms or Personality Traits. 61
30692943 2018
50
The role of cerebellar impairment in emotion processing: a case study. 61
30345063 2018

Variations for Obsessive-Compulsive Personality Disorder

Expression for Obsessive-Compulsive Personality Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Personality Disorder.

Pathways for Obsessive-Compulsive Personality Disorder

GO Terms for Obsessive-Compulsive Personality Disorder

Cellular components related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.65 WASF1 SLITRK1 SLC6A4 SHC4 HTR2A
2 glutamatergic synapse GO:0098978 9.46 SLITRK1 NAPB HTR2A DRD3
3 synapse GO:0045202 9.23 WASF2 WASF1 SLITRK1 SLC6A4 SHC4 NAPB
4 SCAR complex GO:0031209 8.96 WASF2 WASF1

Biological processes related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of dopamine secretion GO:0014059 9.46 HTR2A DRD3
2 response to drug GO:0042493 9.46 SLC6A4 HTR2A DRD3 COMT
3 digestion GO:0007586 9.43 PIR CLPS
4 Rac protein signal transduction GO:0016601 9.4 WASF2 WASF1
5 behavioral response to cocaine GO:0048148 9.37 HTR2A DRD3
6 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.32 HTR2A DRD3
7 dopamine metabolic process GO:0042417 9.26 DRD3 COMT
8 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 8.96 WASF2 WASF1
9 lamellipodium morphogenesis GO:0072673 8.62 WASF2 WASF1

Molecular functions related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A regulatory subunit binding GO:0034237 9.26 WASF2 WASF1
2 protein kinase A binding GO:0051018 9.16 WASF2 WASF1
3 Arp2/3 complex binding GO:0071933 8.96 WASF2 WASF1
4 serotonin binding GO:0051378 8.62 SLC6A4 HTR2A

Sources for Obsessive-Compulsive Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....